Echelon Health, a leader in world-class preventative medicine, is setting a new global benchmark in personalised healthcare with the launch of a revolutionary combined assessment. Clients can now experience the full scope of Echelon’s capabilities by pairing its flagship Platinum Assessment with the newly introduced Dementia Assessment, offering a 360-degree insight into both physical and cognitive health.
Based on Harley Street, London’s renowned medical district, Echelon Health is renowned for delivering unmatched precision in early detection and diagnosis. The Platinum Assessment, its most advanced offering, employs high-resolution imaging including CT, MRI, and ultrasound scans, alongside comprehensive blood analysis, ECGs, and a full-body mole screen. This approach enables the early detection of up to 92% of preventable causes of death in men and 95% in women, empowering clients to take control of their long-term wellbeing.
The service is led by Dr Paul Jenkins, a Cambridge-trained medical expert and Echelon’s founder. Each client receives an in-depth one-on-one consultation, a personalised analysis of their results, and a tailored roadmap for health optimisation or specialist referral where necessary.
Now, with the addition of the Dementia Assessment, Echelon Health is expanding its preventative approach to include the early detection of neurodegenerative conditions. As global cases of dementia rise, the need for pre-symptomatic identification has never been greater. The new assessment integrates extensive blood tests for risk factors such as diabetes, cholesterol, thyroid and vitamin deficiencies, followed by a high definition 3T MRI brain scan interpreted by a leading neuroradiologist.
Clients then undergo the Addenbrooke’s Cognitive Examination (ACE-III), a gold-standard cognitive test with up to 97% sensitivity in detecting early-stage dementia. This neurocognitive evaluation is delivered by Dr. Aijaz Khan, a highly respected Consultant Neurologist with over 25 years’ experience in cognitive decline.
For individuals requiring further investigation, Echelon Health also facilitates access to CT-PET brain imaging, capable of identifying amyloid protein deposits—a key hallmark of Alzheimer’s disease—enabling patients to access the latest disease-slowing treatments at the earliest possible stage.
The Dementia Assessment is priced at £3,000, with 0% interest finance available to increase accessibility. The Platinum Assessment is priced at £14,000 and represents the most comprehensive preventative health service available today.
